1999
DOI: 10.1507/endocrj.46.67
|View full text |Cite
|
Sign up to set email alerts
|

Expression of Asialoglycoprotein Receptor in Human Fetal Liver.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
3
0

Year Published

2005
2005
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 33 publications
1
3
0
Order By: Relevance
“…These data are consistent with available data on placental transfer indicating limited transfer for large negatively charged molecules without active transport (48). Moreover, the GalNAc 3 -conjugated siRNA requires receptor-mediated uptake by the asialoglycoprotein receptor, which is not expressed appreciably in fetal liver until near delivery (49,50). Thus, the use of a maternal livertargeted isoform-specific siRNA in a transgenic model allows the reduced FGR).…”
Section: Discussionsupporting
confidence: 87%
“…These data are consistent with available data on placental transfer indicating limited transfer for large negatively charged molecules without active transport (48). Moreover, the GalNAc 3 -conjugated siRNA requires receptor-mediated uptake by the asialoglycoprotein receptor, which is not expressed appreciably in fetal liver until near delivery (49,50). Thus, the use of a maternal livertargeted isoform-specific siRNA in a transgenic model allows the reduced FGR).…”
Section: Discussionsupporting
confidence: 87%
“…on May 12, 2018. by guest www.bloodjournal.org From other than hAFP or hAlb: CK18, a marker for hepatocytes; AGPR, of which distribution is mainly found on hepatocytes; 34 and CK19, a marker for hepatic progenitor or cholangiocytes (Figure 4). At day 14, all 3 markers were stained diffusely in cytoplasm; at day 28, CK19 was barely detectable, but the intensity for CK18 and AGPR rather increased.…”
Section: Human Mscs Give Rise To Liver With No Fusion In Rat 759mentioning
confidence: 99%
“…The developed and validated PBPK model in pregnant women can be further developed by incorporating a fetal compartment to a maternal-fetal PBPK (mf-PBPK) model to predict placental and fetal transfer of siRNA. For example, ASGPR has been shown to be expressed in the human placenta (Vyas et al, 2018) and detected in fetal liver tissue (Yoshida et al, 1999). This expression pattern can be incorporated into the mf-PBPK model to predict transplacental transfer and fetal exposure of GalNAc-siRNA to assess fetal risk from maternal siRNA exposure.…”
Section: Pbpk Modeling To Predict Sirna Disposition During Pregnancymentioning
confidence: 99%